|

Industry NEWS: The GOOD, The BAD, And The UGLY / New Psychedelic Studies, Legalization Bills & MORE!

ByPsychedelic Spotlight

Hey guys! In this week’s general industry news, we’ll cover some interesting developments. Some are probably going to make some of our viewers turn away from this week’s episode as they discover some pretty “depressing” statistics about North America’s current mental state. However, for those who stick around, you might end up finding that there might be a light at the end of the tunnel as you discover that psilocybin’s benefits might be extended to treat certain

Enjoy!
Links:
Psilocybin & Migraines: https://www.psypost.org/2021/05/a-single-dose-of-psilocybin-has-a-lasting-therapeutic-effect-on-migraine-headache-according-to-a-new-placebo-controlled-study-60793

Increased depression in North America:
https://www.meetfieldtrip.com/news/news-details/2021/Canadians-Are-Not-OK-83-of-Canadians-Report-One-Or-More-Symptoms-of-Depression-With-Many-Turning-To-Substances-To-Cope-With-Negative-Emotions-During-COVID-19-Pandemic-According-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx

https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx

Opioid Overdose In Ontario:
https://www.cp24.com/news/opioid-overdose-deaths-up-75-per-cent-in-ontario-during-covid-19-pandemic-new-report-1.5434080

FDA Greenlights Ketamine:

FDA Green-Lights Ketamine Study for Side Effects of Parkinson’s Disease Treatment

California Bill to Decriminalize Psychedelics Passes Senate Floor:

California Bill To Legalize Possession Of Psychedelics Heads To Senate Floor After Committee Action

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #PsychedelicIndustry

Similar Posts

  • HAVN’s Cluster Headache Treatment BETTER Than Mindmed’s? (HAVN CEO Interview)

    Listen, Videos

    HAVN VS. Mindmed – Whose Cluster Headache Treatment Is Better?

    Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our “This Week In Psychedelic Stocks” segment.
    In light of HAVN’s recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore.

    HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind.

    Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020.

    The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms.

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) .

    https://havnlife.com/
    CSE: HAVN | OTC: HAVLF | FRA: 5NP

    #HAVN #HAVNLifeSciences #Mindmed

  • This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]

    Listen, Videos

    In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.

    We will cover the latest developments in the field writ large.
    This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

    Timestamps:
    0:00 – Intro
    0:32 – Norway Decriminalization Bill
    1:59 – Psychedelic Market Stats
    3:21 – Magic Mushrooms to Treat Obesity
    5:40 – Ketamine to Treat Suicidal Thoughts?
    7:09 -The Acid King?
    8:58 – MindMed (MMED/MMEDF/MMQ) Updates
    10:04 – Compass Pathways (CMPS) Updates
    11:44 – Atai Life Sciences Updates
    14:02 – Numinus (NUMI) Updates
    15:13 – CYBIN Updates

    So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​#MindmedStock​​ #PsychedelicStocks

  • Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences

    Interviews, Listen, Podcasts

    In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.